SG11202012596YA - Compound and use thereof in synthesis of brivaracetam intermediate and crude drug - Google Patents
Compound and use thereof in synthesis of brivaracetam intermediate and crude drugInfo
- Publication number
- SG11202012596YA SG11202012596YA SG11202012596YA SG11202012596YA SG11202012596YA SG 11202012596Y A SG11202012596Y A SG 11202012596YA SG 11202012596Y A SG11202012596Y A SG 11202012596YA SG 11202012596Y A SG11202012596Y A SG 11202012596YA SG 11202012596Y A SG11202012596Y A SG 11202012596YA
- Authority
- SG
- Singapore
- Prior art keywords
- synthesis
- compound
- crude drug
- brivaracetam intermediate
- brivaracetam
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810651559 | 2018-06-22 | ||
| PCT/CN2019/092105 WO2019242692A1 (zh) | 2018-06-22 | 2019-06-20 | 化合物及其在合成布瓦西坦(Brivaracetam)中间体及原料药中的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012596YA true SG11202012596YA (en) | 2021-02-25 |
Family
ID=68983441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012596YA SG11202012596YA (en) | 2018-06-22 | 2019-06-20 | Compound and use thereof in synthesis of brivaracetam intermediate and crude drug |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11247977B2 (de) |
| EP (1) | EP3798211A4 (de) |
| JP (1) | JP7117796B2 (de) |
| KR (1) | KR102544330B1 (de) |
| CN (1) | CN111094260B (de) |
| AU (1) | AU2019291703B2 (de) |
| CA (1) | CA3103332C (de) |
| SG (1) | SG11202012596YA (de) |
| WO (1) | WO2019242692A1 (de) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108689968B (zh) * | 2015-05-25 | 2020-09-15 | 苏州鹏旭医药科技有限公司 | 两种化合物及其制备方法和在合成布瓦西坦中的用途 |
| KR102630456B1 (ko) | 2015-05-25 | 2024-01-29 | 쑤저우 펭슈 파마테크 씨오., 엘티디. | 브리바라세탐의 제조 방법 |
| CN106432030B (zh) * | 2015-10-10 | 2019-06-25 | 苏州鹏旭医药科技有限公司 | 布瓦西坦的一种制备方法 |
| CN105646319B (zh) | 2015-12-30 | 2018-05-18 | 佛山市隆信医药科技有限公司 | 一种布瓦西坦的制备方法 |
| CN105837535A (zh) | 2016-04-06 | 2016-08-10 | 成都拿盛科技有限公司 | 一种取代的手性γ-丁内酯的合成方法 |
| CN105801530A (zh) | 2016-04-13 | 2016-07-27 | 成都拿盛科技有限公司 | 一种4位取代的手性γ-丁内酯的合成方法 |
| CN106008411A (zh) | 2016-05-26 | 2016-10-12 | 上海华默西医药科技有限公司 | 手性4-取代基二氢呋喃-2(3h)-酮的制备方法 |
| CN107652254A (zh) | 2017-11-14 | 2018-02-02 | 安徽华胜医药科技有限公司 | 一种制备丁内酯衍生物的方法 |
| CN109134406A (zh) | 2018-08-02 | 2019-01-04 | 丽珠集团新北江制药股份有限公司 | 一种布瓦西坦中间体及布瓦西坦的合成方法 |
| CN112154140B (zh) | 2019-01-09 | 2023-11-24 | 福建海西新药创制股份有限公司 | 化合物及其在合成布瓦西坦(Brivaracetam)原料药中的用途 |
-
2019
- 2019-06-20 EP EP19821607.9A patent/EP3798211A4/de active Pending
- 2019-06-20 AU AU2019291703A patent/AU2019291703B2/en active Active
- 2019-06-20 CN CN201980004099.3A patent/CN111094260B/zh active Active
- 2019-06-20 US US17/253,135 patent/US11247977B2/en active Active
- 2019-06-20 SG SG11202012596YA patent/SG11202012596YA/en unknown
- 2019-06-20 WO PCT/CN2019/092105 patent/WO2019242692A1/zh unknown
- 2019-06-20 JP JP2020571581A patent/JP7117796B2/ja active Active
- 2019-06-20 KR KR1020217000396A patent/KR102544330B1/ko active IP Right Grant
- 2019-06-20 CA CA3103332A patent/CA3103332C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7117796B2 (ja) | 2022-08-15 |
| AU2019291703A1 (en) | 2021-01-21 |
| EP3798211A4 (de) | 2021-09-15 |
| KR20210018454A (ko) | 2021-02-17 |
| CN111094260A (zh) | 2020-05-01 |
| US20210261515A1 (en) | 2021-08-26 |
| KR102544330B1 (ko) | 2023-06-20 |
| EP3798211A1 (de) | 2021-03-31 |
| CA3103332A1 (en) | 2019-12-26 |
| CA3103332C (en) | 2023-03-07 |
| AU2019291703B2 (en) | 2021-09-23 |
| WO2019242692A1 (zh) | 2019-12-26 |
| CN111094260B (zh) | 2021-05-11 |
| JP2021528440A (ja) | 2021-10-21 |
| US11247977B2 (en) | 2022-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202009574RA (en) | Combinations of osteopontin and 2'-fucosyllactose for use as medicaments | |
| IL272060A (en) | Compositions containing cannabinoids and methods of using them | |
| IL273339A (en) | Griseofulbin compound and its medical use | |
| GB201819957D0 (en) | Novel quinazolinone derivatives inhibiting piek and pharmaceutical composition containing same | |
| SG11202112129SA (en) | Drug conjugates and methods of using same | |
| IL280596A (en) | Anti-IL-1 antibody in a cell, its pharmaceutical preparation and its use | |
| EP3773654C0 (de) | Pharmazeutische wirkstoffzusammensetzungen und zugehörige verfahren | |
| IL283522A (en) | Pharmaceutical preparations containing anti-191p4d12 antibody drug conjugates and methods of using them | |
| SG11202004693PA (en) | Synthesis of morin and morin derivatives | |
| IL276311A (en) | Methyllactam ring compound and its pharmaceutical use | |
| IL276323A (en) | 4-Methyldihydropyrimidinone compounds and their pharmaceutical use | |
| ZA201901263B (en) | Crystals of cyclic amine derivative and pharmaceutical use thereof | |
| IL274433A (en) | Fulvestrant formulations and methods of using them | |
| EP3880183A4 (de) | Pharmazeutische zubereitung von fruquintinib und verwendung davon | |
| EP3615064A4 (de) | Angereicherte zellzusammensetzungen und therapeutische verwendung | |
| SG11202012596YA (en) | Compound and use thereof in synthesis of brivaracetam intermediate and crude drug | |
| ZA202100166B (en) | Composition comprising glycyrrhin and cosmetic and pharmaceutical uses thereof | |
| EP4079305A4 (de) | Anwendung einer verbindung in einer arzneimittelzubereitung | |
| IL271596A (en) | Preparations for administering drugs and methods of using them | |
| ZA202000959B (en) | Adamantylmethylamine derivative and use thereof as pharmaceutical | |
| IL271875B (en) | Preparations containing totarol and their use | |
| HK1246778A1 (zh) | 一種新型的3-氮雜雙環[3.1.0]己烷衍生物的鹽的晶體以及其醫藥應用 | |
| IL282566A (en) | Synthesis of (S)-6-hydroxytryptophan and their derivatives | |
| TWI844581B (zh) | 呋喹替尼製劑及其應用 | |
| IL273904A (en) | Medicinal resin components and methods for their production and use |